{"id":"crossover-ino","safety":{"commonSideEffects":[{"rate":null,"effect":"Methemoglobinemia"},{"rate":null,"effect":"Nitrogen dioxide exposure"},{"rate":null,"effect":"Rebound pulmonary hypertension upon discontinuation"}]},"_chembl":{"chemblId":"CHEMBL5095348","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nitric oxide is a potent pulmonary vasodilator that selectively reduces pulmonary artery pressure and improves ventilation-perfusion matching in the lungs. By delivering iNO via inhalation, the drug acts locally on pulmonary vasculature to improve gas exchange and oxygen delivery while minimizing systemic effects. This mechanism is particularly useful in conditions characterized by pulmonary hypertension and hypoxemia.","oneSentence":"Crossover iNO is an inhaled nitric oxide delivery system that increases nitric oxide levels in the lungs to improve oxygenation and reduce pulmonary vascular resistance.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:31:24.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute respiratory distress syndrome (ARDS)"},{"name":"Pulmonary hypertension in critically ill patients"},{"name":"Hypoxemic respiratory failure"}]},"trialDetails":[{"nctId":"NCT04476238","phase":"NA","title":"Inosine Energy Expenditure Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-02-28","conditions":"Healthy Volunteers","enrollment":8},{"nctId":"NCT01891500","phase":"PHASE4","title":"Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2016-05","conditions":"Persistent Fetal Circulation Syndrome, Hypertension, Pulmonary, of Newborn, Persistent, Persistent Pulmonary Hypertension of Newborn","enrollment":""},{"nctId":"NCT02614469","phase":"PHASE1","title":"A Food-Drug Interaction Study of Serum Urate After Oral Inosine","status":"COMPLETED","sponsor":"Michael Alan Schwarzschild","startDate":"2015-03","conditions":"Healthy","enrollment":18},{"nctId":"NCT00924846","phase":"PHASE3","title":"High-Frequency Oscillatory Ventilation Associated With Inhaled Nitric Oxide in Children","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2005-04","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["bioinert","INOmax"],"phase":"marketed","status":"active","brandName":"Crossover iNO","genericName":"Crossover iNO","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Crossover iNO is an inhaled nitric oxide delivery system that increases nitric oxide levels in the lungs to improve oxygenation and reduce pulmonary vascular resistance. Used for Acute respiratory distress syndrome (ARDS), Pulmonary hypertension in critically ill patients, Hypoxemic respiratory failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}